Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

January 27, 2020

Study Completion Date

March 4, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

BTX 1204

BTX 1204 liquid formulation

DRUG

Vehicle

Vehicle liquid formulation

Trial Locations (31)

1010

Optimal Clinical Trials, Auckland

2145

The Skin Hospital, Westmead

2217

Premier Specialists PTY LTD, Kogarah

St George Dermatology & Skin Cancer Center, Kogarah

3002

Sinclair Dermatology, East Melbourne

3204

Clinical Trials New Zealand LTD, Hamilton

4102

Veracity Clinical Research, Woolloongabba

5000

CMAX Clincial Research, Adelaide

5073

North Eastern Health Specialists, Hectorville

6009

Captain Stirling Medical Centre, Nedlands

6021

P3 Research, Wellington

6100

BurwoodDermatology, Burwood

29607

Greenville Dermatology, LLC, Greenville

33162

Troy Sullivan, North Miami Beach

33328

Precision Clinical Research, Davie

40241

DS Research, Louisville

43016

Aventiv Research Inc - Dublin, Dublin

63141

Washington Univerisy in St. Louis, St Louis

64506

Medisearch Clinical Trails, Saint Joseph

70115

Delright Research, New Orleans

72212

Applied Research Center of Arkansas Inc., Little Rock

77056

The Center for Skin Research at Suzanne Bruce & Associates Dermatology, Houston

77845

J&S Studies Inc., College Station

78759

Dermresearch Inc, Austin

89148

JDR Dermatology Research LLC, Las Vegas

90404

Clinical Science Institute, Santa Monica

91436

T. Joseph Raoff MD Inc. / Encino Research Center, Encino

92123

Rady Childern's Hospital - San Diego, San Diego

92562

Dermatology Specialist Inc. - Murrieta, Murrieta

94538

Center for Dermatology Clinical Research, Fremont

07960

The Acne Treatment and Research Center, Morristown

Sponsors
All Listed Sponsors
lead

Botanix Pharmaceuticals

INDUSTRY